Outset Medical (NASDAQ:OM) Upgraded to Hold at Wall Street Zen

Outset Medical (NASDAQ:OM) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

OM has been the topic of several other reports. Stifel Nicolaus dropped their target price on Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a research note on Monday, December 29th. BTIG Research dropped their price target on shares of Outset Medical from $17.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $7.00 target price on shares of Outset Medical in a report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Outset Medical Trading Up 1.1%

Shares of NASDAQ:OM opened at $3.56 on Friday. The stock’s fifty day moving average price is $3.98 and its 200-day moving average price is $7.23. Outset Medical has a 1 year low of $3.00 and a 1 year high of $21.98. The company has a market cap of $65.18 million, a P/E ratio of -0.52 and a beta of 2.12. The company has a debt-to-equity ratio of 0.76, a current ratio of 6.67 and a quick ratio of 5.40.

Insider Activity

In other news, General Counsel John L. Brottem sold 9,314 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $47,687.68. Following the transaction, the general counsel owned 36,957 shares of the company’s stock, valued at approximately $189,219.84. The trade was a 20.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Marc Nash sold 5,375 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total value of $27,520.00. Following the completion of the sale, the executive vice president owned 42,785 shares of the company’s stock, valued at approximately $219,059.20. This represents a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 40,910 shares of company stock valued at $193,040. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Geode Capital Management LLC boosted its holdings in Outset Medical by 955.9% during the 2nd quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock valued at $7,984,000 after acquiring an additional 376,196 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new stake in Outset Medical in the second quarter worth $78,000. JPMorgan Chase & Co. lifted its position in shares of Outset Medical by 662.8% during the second quarter. JPMorgan Chase & Co. now owns 8,452 shares of the company’s stock worth $162,000 after purchasing an additional 7,344 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of Outset Medical during the second quarter worth $34,000. Finally, Rhumbline Advisers purchased a new stake in shares of Outset Medical during the second quarter valued at $499,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.